Serhal Maya, Longenecker Chris T
University Hospitals Case Medical Center, Cleveland, OH, USA.
University Hospitals Case Medical Center, Cleveland, OH, USA ; Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Curr Cardiovasc Risk Rep. 2014 Jun;8(8). doi: 10.1007/s12170-014-0392-7.
Patients with chronic inflammatory diseases are at increased risk for heart failure due to ischemic heart disease and other causes including heart failure with preserved ejection fraction. Using rheumatoid arthritis and treated HIV infection as two prototypical examples, we review the epidemiology and potential therapies to prevent heart failure in these populations. Particular focus is given to anti-inflammatory therapies including statins and biologic disease modifying drugs. There is also limited evidence for lifestyle changes and blockade of the renin-angiotensin-aldosterone system. We conclude by proposing how a strategy for heart failure prevention, such as the model tested in the Screening To Prevent Heart Failure (STOP-HF) trial, may be adapted to chronic inflammatory disease.
患有慢性炎症性疾病的患者因缺血性心脏病和其他原因（包括射血分数保留的心力衰竭）而患心力衰竭的风险增加。以类风湿性关节炎和接受治疗的HIV感染这两个典型例子为例，我们回顾了这些人群中预防心力衰竭的流行病学和潜在疗法。特别关注了包括他汀类药物和生物疾病改善药物在内的抗炎疗法。生活方式改变和肾素-血管紧张素-醛固酮系统阻断的证据也有限。我们通过提出如何将心力衰竭预防策略（如在预防心力衰竭筛查试验（STOP-HF）中测试的模型）应用于慢性炎症性疾病来得出结论。
